Investigation of serum proteome alterations in human glioblastoma multiforme
暂无分享,去创建一个
Aliasgar Moiyadi | Sanjeeva Srivastava | Sandipan Ray | Kishore Gollapalli | Prateek Singh | Rajneesh Srivastava | Sanjeeva Srivastava | Kishore Gollapalli | Sandipan Ray | A. Moiyadi | Snigdha Dhali | Durairaj Renu | Snigdha Dhali | Jyoti Bajpai Dikshit | Rapole Srikanth | D. Renu | Jyoti Bajpai Dikshit | R. Srivastava | R. Srikanth | Prateek Singh
[1] M. Schuhmann,et al. Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[2] G. Reifenberger,et al. The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.
[3] Anushya Muruganujan,et al. Applications for protein sequence–function evolution data: mRNA/protein expression analysis and coding SNP scoring tools , 2006, Nucleic Acids Res..
[4] A. Kandutsch,et al. The role of cholesterol in malignancy. , 1978, Progress in experimental tumor research.
[5] Vani Santosh,et al. Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. , 2010, Journal of proteome research.
[6] L. Deangelis,et al. Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas , 2011, Journal of Neuro-Oncology.
[7] H. Ginsberg,et al. Hypocholesterolemia and acute myelogenous leukemia: Association between disease activity and plasma low‐density lipoprotein cholesterol concentrations , 1986, Cancer.
[8] J. Bertolini,et al. Therapeutic potential of vitamin D-binding protein. , 2004, Trends in biotechnology.
[9] B. Efron,et al. The possible prognostic usefulness of assessing serum proteins and cholesterol in malignancy , 1975, Cancer.
[10] N. Tsopanoglou,et al. On the mechanism(s) of thrombin induced angiogenesis. , 2000, Advances in experimental medicine and biology.
[11] James P Basilion,et al. A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu. , 2010, Neoplasia.
[12] B. Mittal,et al. High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance , 2010, NMR in Biomedicine.
[13] William Arbuthnot Sir Lane,et al. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. , 1999, Science.
[14] Harish Srinivasan,et al. Identification of Potential Serum Biomarkers of Glioblastoma: Serum Osteopontin Levels Correlate with Poor Prognosis , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[15] A. Kaye,et al. The role of the plasminogen activation cascade in glioma cell invasion: a review , 2003, Journal of Clinical Neuroscience.
[16] M. Kiechle,et al. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. , 2002, Clinical breast cancer.
[17] A. Sotgiu,et al. Lipid Metabolism Impairment in Human Gliomas: Expression of Peroxisomal Proteins in Human Gliomas at Different Grades of Malignancy , 2010, International journal of immunopathology and pharmacology.
[18] M. Mann,et al. In-gel digestion for mass spectrometric characterization of proteins and proteomes , 2006, Nature Protocols.
[19] U. Fischer,et al. Vitamin D3 Metabolism in Human Glioblastoma Multiforme: Functionality of CYP27B1 Splice Variants, Metabolism of Calcidiol, and Effect of Calcitriol , 2005, Clinical Cancer Research.
[20] P. Grieb,et al. Serum Cholesterol in Cerebral Malignancies , 2004, Journal of Neuro-Oncology.
[21] A. Kyritsis,et al. Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy , 2010, Journal of Neuroimmunology.
[22] N. Gogtay,et al. Serum proteome analysis of vivax malaria: An insight into the disease pathogenesis and host immune response. , 2012, Journal of proteomics.
[23] R. Fimmers,et al. Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients , 2009, Clinical Cancer Research.
[24] J. Chang-Claude,et al. The Gc2 Allele of the Vitamin D Binding Protein Is Associated with a Decreased Postmenopausal Breast Cancer Risk, Independent of the Vitamin D Status , 2008, Cancer Epidemiology Biomarkers & Prevention.
[25] F. Howe,et al. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. , 2008, Clinical chemistry.
[26] S. Horvath,et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer , 2007, Proceedings of the National Academy of Sciences.
[27] S. Cha. CNS Tumors: Monitoring Therapeutic Response and Outcome Prediction , 2006, Topics in magnetic resonance imaging : TMRI.
[28] A. Basdevant. Steroids and lipid metabolism: mechanism of action. , 1992, International journal of fertility.
[29] L. Deangelis,et al. YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas , 2006, Clinical Cancer Research.
[30] H. Steinmetz,et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. , 2007, Brain : a journal of neurology.
[31] Sanjeeva Srivastava,et al. Proteomic technologies for the identification of disease biomarkers in serum: Advances and challenges ahead , 2011, Proteomics.
[32] C. Ríos,et al. Plasma Ceruloplasmin Ferroxidase Activity Correlates with the Nigral Sonographic Area in Parkinson’s Disease Patients: A Pilot Study , 2011, Neurochemical Research.
[33] S. Pradhan,et al. In vitro, high‐resolution 1H and 31P NMR based analysis of the lipid components in the tissue, serum, and CSF of the patients with primary brain tumors: one possible diagnostic view , 2009, NMR in biomedicine.
[34] J. Weiss,et al. Serum acute-phase proteins and immunoglobulins in patients with gliomas. , 1979, Cancer research.
[35] H. Birkedal‐Hansen,et al. Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[36] Jean-Pierre Julien,et al. Ceruloplasmin Regulates Iron Levels in the CNS and Prevents Free Radical Injury , 2002, The Journal of Neuroscience.
[37] T. Schallert,et al. The role of thrombin in gliomas , 2005, Journal of thrombosis and haemostasis : JTH.
[38] L. Turecký,et al. Serum ceruloplasmin and copper levels in patients with primary brain tumors , 1984, Klinische Wochenschrift.
[39] S. Niclou,et al. Glioma proteomics: status and perspectives. , 2010, Journal of proteomics.
[40] S. Brem,et al. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. , 1998, Journal of neurosurgery.
[41] G. Butti,et al. Vitamin D Metabolites Activate the Sphingomyelin Pathway and Induce Death of Glioblastoma Cells , 1998, Acta Neurochirurgica.
[42] Jean Mosser,et al. Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach , 2011, Proteome Science.
[43] M. Shibuya. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor , 2009, The FEBS journal.
[44] Douglas S Rehder,et al. Glycosylation status of vitamin D binding protein in cancer patients , 2009, Protein science : a publication of the Protein Society.
[45] J. Gurney,et al. Brain and other central nervous system tumors: rates, trends, and epidemiology , 2001, Current opinion in oncology.
[46] A. Avgerinos,et al. Serum lipids and lipoprotein disorders in cancer patients , 1987, Cancer.
[47] Paul S Mischel,et al. Molecular Analysis of Glioblastoma: Pathway Profiling and Its Implications for Patient Therapy , 2003, Cancer biology & therapy.
[48] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[49] H. Hasan,et al. Study of Lipoproteins in Patients with Brain Tumors , 2009 .
[50] K. Somasundaram,et al. Serum proteomics of glioma: methods and applications , 2009, Expert review of molecular diagnostics.
[51] P. Kleihues,et al. Molecular pathogenesis of astrocytic tumours , 2004, Journal of Neuro-Oncology.